• Inicio
  • Formações
  • Formação à Medida
  • News & Trends
  • Sobre nós
  • Contacto

Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties

FDA GUIDANCE SNAPSHOT:
Conducting Clinical Trials With Decentralized Elements. Guidance for Industry, Investigators, and Other Interested Parties

This guidance provides FDA’s recommendations for sponsors, investigators, and other interested parties regarding the implementation of decentralized elements in clinical trials.

OCTOBER 2026

News & Trends

Procurar

Recentes

  • FDA Biosimilar Development – Q&A Guidance: Q&As on Biosimilar Development and the BPCI Act
  • NDSG workplan 2026-2028 : Data and AI in medicines regulation
  • New guidance on the conduct of clinical trials during public health emergencies
  • Nova lei regula ensaios clínicos de medicamentos para uso humano em Portugal
  • FDA draft guidance :“New Clinical Investigation Exclusivity: 3-Year Exclusivity for Drug Products – Questions and Answers.”
  • webinar INTELIGÊNCIA ARTIFICIAL NA INDÚSTRIA FARMACÊUTICA :IA EM CONTEXTO GxP (Annex 11, 22, EU AI Act , GAMP®)
  • GESTÃO da DISPONIBILIDADE do MEDICAMENTO: “Formação muito útil !
  • IMDRF Playbook for Medical Device Regulatory Reliance Programs

91 257 00 03 (Chamada para a rede móvel nacional)
info@formiventos.com

  • Follow
  • CLIENTES & TESTIMONIALS
  • ASSOCIAÇÕES OFICIAIS
  • CERTIFICAÇÕES E CREDITAÇÕES
  • ADVISORY BOARD
  • Política de Privacidade
  • Contacto